key: cord-0887630-gocq10nz authors: Nguyen, Alan A.; Habiballah, Saddiq B.; Platt, Craig D.; Geha, Raif S.; Chou, Janet S.; McDonald, Douglas R. title: Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!() date: 2020-05-11 journal: Clin Immunol DOI: 10.1016/j.clim.2020.108459 sha: 12bd8625743f7f7228c90e79baf445b6a223b821 doc_id: 887630 cord_uid: gocq10nz The COVID-19 pandemic is one of the greatest infectious challenges in recent history. Presently, few treatment options exist and the availability of effective vaccines is at least one year away. There is an urgent need to find currently available, effective therapies in the treatment of patients with COVID-19 infection. In this review, we compare and contrast the use of intravenous immunoglobulin and hyperimmune globulin in the treatment of COVID-19 infection. The novel coronavirus disease 2019 pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), poses an unprecedented challenge to clinicians and strain on the healthcare system due to its high rate of infectivity (R o ) and mortality. Currently, there is no consensus on treatment algorithms for COVID-19, as the evidence available is not well controlled and largely anecdotal. Given rapid and catastrophic spread of COVID-19, there is an urgent need to explore pre-existing therapeutic options while novel therapies and vaccines are being developed. Intravenous immunoglobulin (IVIG) is a product derived from the plasma of thousands of donors used for treatment of primary and secondary immunodeficiencies, autoimmune/inflammatory conditions, neuroimmunologic disorders, and infectionrelated sequelae. IVIG provides passive immune protectio n against a broad range of pathogens. Hyperimmune globulin, in contrast, is derived from individuals with high antibody titers to specific pathogens and has been used successfully in the treatment of infections, such as cytomegalovirus and H1N1 influenza. Here, we review the mechanism and utility of IVIG and hyperimmune globulin in viral infections, and consider their usage in COVID-19 infection (Table 1) . The entry of SARS-CoV-2 into host cells is mediated by the transmembrane spike (S) glycoprotein that binds to the angiotensin converting enzyme 2 (ACE2) receptor, which is highly expressed on the apical surface of many cell types, including airway epithelial cells. The S protein forms a homotrimer that protrudes from the viral surface. Receptor binding is mediated by the S 1 subunit through the receptor binding J o u r n a l P r e -p r o o f domain (RBD). After binding to the ACE2 receptor, proteolytic activation of the S 2 subunit mediates the fusion between the viral and the cellular membranes(1). Due to the essential role of S glycoprotein in cellular infection, antibodies that bind to S 1 and S 2 can prevent infection (Fig. 1) , as demonstrated in cell cultures by incubating virus in the presence of neutralizing antibody and quantitating reduction in viral intracellular RNA levels (2) . A neutralizing antibody can stop viral replication by blocking receptor binding, preventing wall fusion, or preventing uncoating of the virus once inside the cytoplasm. Analyses of patients infected with SARS-CoV has revealed seroconversion four days following disease onset in some individuals and the majority of patients seroconverted between two to three weeks of disease onset in patients infected with either SARS-CoV or Middle East Respiratory syndrome (MERS-CoV) (3, 4) . Weak or delayed antibody responses were associated with poor outcomes. Analysis of SARS-CoV convalescent human plasma revealed that SARS-neutralizing antibodies peaked at four months post recovery, but were undetectable in 16% of patients at 36 months. is generally associated with more severe immune deficiency than X-linked agammaglobulinemia and variable B and T cell defects, suggesting a critical role for cellular immunity against COVID-19. As will be discussed below, the presence of antiviral antibodies can be associated with exacerbation of disease. IVIG was first licensed in the United States in 1980 and is a highly effective therapy for the prevention of life -threatening infections in patients with primary and secondary immune deficiencies (Table 1) Several anti-inflammatory mechanisms of IVIG may lessen the inflammatory response in severe SARS-CoV-2 infection, including the presence autoreactive antibodies that bind cytokines or binding to the variable domains of other antibodies (anti-idiotypic antibodies) (Fig.1) . Additionally, the presence of IgG dimers in IVIG may block activating FcR on innate immune effector cells(11) (Fig. 1 ). There is a case series on IVIG usage The study suggests that IVIG led to significant improvement in leukocyte and platelet counts, but acknowledges that there was no control group to objectively evaluate responses (14) . A single center retrospective study in Singapore found that adult SARS patients treated with a regimen of pulse methylprednisolone (400 mg) and IVIG (0.4 mg/kg) daily for three consecutive days had an adjusted hazard ratio of 0.41 for mortality compared to the untreated group, with a trend towards earlier recovery. However, this finding was not statistically significant (95% CI 0.14-1.23; P=0.11). Furthermore, this result was confounded by the concurrent use of steroids (15) . There are two case reports of IVIG used in MERS. One patient received IVIG with high-dose corticosteroids due to thrombocytopenia, with resulting improvement in platelet count. Similar to the previous study, there was concurrent steroid use and, moreover, the patient's overall clinical co urse is unknown (16) . Thus, the field lacks strong evidence to support the use of IVIG for the treatment of coronaviruses, such as SARS-CoV, SARS-CoV-2, and MERS. More robust evidence exists for the use of hyperimmune globulin in the treatment viral illnesses ( (19) . While antibodies against coronaviruses, including SARS-CoV, MERS-CoV and SARS-CoV-2 play an important role in host defense against these infections, there is concern that antibodies can trigger a harmful, exaggerated inflammatory response in a process termed antibody-dependent enhancement (ADE) (Fig. 1) . Previously, ADE has been proposed as an underlying pathogenic mechanism in Dengue hemorrhagic fever. Pre-existing, subneutralizing antibodies form immune complexes with virus which bind to FcR-bearing cells, leading to increased viral uptake and replication (20) . Plasma that elicit ADE-induced inflammation was found to be present in patients with earlier onset of production of SARS-CoV IgG and more severe clinical courses. The COVID-19 pandemic represents one of the most widespread infectious challenges in recent times. As of the time of this publication, COVID-19 is responsible for greater than 250,000 deaths worldwide and the count continues to increase on a daily basis. The search for effective antiviral therapies and treatment is ongoing. Vaccine development is progressing at a rapid pace, but widespread vaccine availability is estimated to be at least one year away. There is an urgent need for effective interventions presently. Performing a randomized controlled trial with a placebo arm in the midst of a deadly pandemic is extremely challenging. Until herd immunity develops against SARS-CoV-2, preferably by means of effective vaccines, the global population will remain at risk. Past experience has demonstrated that vaccine development needs to be performed cautiously to avoid potential exacerbation of disease (i.e. ADE). Use of hyperimmune globulin has demonstrated clear effectiveness in the treatment of J o u r n a l P r e -p r o o f Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody re sponses during infection by SARS-CoV-2: an observational cohort study Antibody responses to SARS-CoV-2 in patients with COVID-19 Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis Hepatitis B Surface Antigen Seroclearance: Immune Mechanisms, Clinical Impact, Importance for Drug Development Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis Downfall of the current antibody correlates of influenza vaccine response in yearly vaccinated subjects: Toward qualitative rather than quantitative assays Intravenous immunoglobulin therapy: how does IgG modulate the immune system? High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease SARS: systematic review of treatment effects Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia Use of convalescent plasma therapy in SARS patients in Hong Kong Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection Review of dengue virus and the development of a vaccine Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection Although placebo-controlled studies demonstrating the effectiveness of intravenous immunoglobulin the treatment of COVID-19 infection are lacking, intravenous immunoglobulin shows promise in modulating the excessive inflammation associated with severe COVID-19 infection. Randomized, controlled studies have demonstrated the effectiveness of hyperimmune globulin derived from convalescent COVID-19 patients. Caution in the use of immunoglobulins in the treatment of severe COVID-19 infection, since antibodies have been associated with excessive inflammation in viral infection.